LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Medix Biochemica Acquires IVD Raw Materials Producer Bioresource Technology

By LabMedica International staff writers
Posted on 21 Jun 2022
Print article
Image: Medix Biochemica has broadened its capabilities in diagnostic base matrices through the acquisition of BRT (Photo courtesy of Pexels)
Image: Medix Biochemica has broadened its capabilities in diagnostic base matrices through the acquisition of BRT (Photo courtesy of Pexels)

Medix Biochemica (Espoo, Finland) has acquired 100% of the shares of Bioresource Technology (BRT, Weston, FL, USA) to broaden its base matrix capabilities and further strengthen its local presence in the US market. As a result of this partnership, Medix will provide its customers with a comprehensive offering of raw materials for their in vitro diagnostics (IVD) quality control products.

BRT is a leading provider of high-quality base matrices and other critical raw materials to many of the largest IVD manufacturers across the world, with a focus on manufacturing immunoassay, clinical chemistry and molecular diagnostic assay and QC materials. BRT’s organization and operations will form a significant part of Medix’s IVD Biomaterials Business Unit, which also comprises manufacturing of native antigens, enzymes, proteins and biological.

“Together, we have the potential to broaden our offering to IVD companies across the globe,” said Steve Ferguson, CEO of Medix Biochemica. “There is an excellent complementary offering between our portfolios, enabling Medix Biochemica to be a comprehensive partner for IVD companies requiring quality raw materials for QC products. With our complete offering of biological samples, processed plasma, base matrices, native enzymes, proteins, antibodies or antigens and our depth of expertise, we can dramatically reduce time to market for IVD companies whatever their need. Our vision is to be the first-choice partner for the IVD industry, and the team at BRT takes us one step closer.”

“We are excited about joining Medix Biochemica,” addd Derik Reichenbach, President of BRT. “Building long-term relationships with our customers have always been key to our success and together with Medix Biochemica’s global team, we are now able to reach even more IVD customers across the globe. We are very much looking forward to contributing to the strong growth of Medix Biochemica.”

Related Links:
Medix Biochemica 
Bioresource Technology 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more